N/A N=29 Randomized Other

Exendin-9,39 and Satiety After Bariatric Surgery

Obesity

Bottom Line

View on ClinicalTrials.gov: NCT02779075 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2020

Primary outcome: Primary: Caloric Intake — 531; 465; 444; 494 calories

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Saline (Drug); Exendin-9,39 (Drug)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Jul 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Caloric Intake	531; 465; 444; 494	—
SECONDARY Gastrointestinal Transit Measured Using Scintigraphy	63; 48; 100; 141	—

Summary

The overall aim of the application is to determine the contribution of the elevated incretin hormone concentrations seen after certain types of bariatric surgery to the regulation of food intake and satiety.

Eligibility Criteria

Inclusion Criteria

Undergone either sleeve gastrectomy or Roux-en-Y Gastric Bypass surgery within prior 2 years
Healthy, with no active systemic illness

Exclusion Criteria

Pregnancy
Functional or organic bowel symptoms
Systemic illness
Diabetes
Bariatric surgery > 2 years

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02779075). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.